66 related articles for article (PubMed ID: 20484367)
1. Age and CD4 count of vertically HIV-infected children at the time of diagnosis: what are independent predictors for being symptomatic and CD4 counts drop?
Berhan Y
J Trop Pediatr; 2011 Feb; 57(1):14-23. PubMed ID: 20484367
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
3. Change in absolute CD4 count with antiretroviral treatment in resource limited setting: a retrospective cohort study in children in Ethiopia.
Berhan Y
Ethiop Med J; 2011 Oct; 49(4):289-98. PubMed ID: 23409394
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
5. Neurodevelopmental outcomes in children with HIV infection under 3 years of age.
Foster CJ; Biggs RL; Melvin D; Walters MD; Tudor-Williams G; Lyall EG
Dev Med Child Neurol; 2006 Aug; 48(8):677-82. PubMed ID: 16836781
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of vitamin B12 and folate in vertically infected children with HIV-1.
Malik ZA; Abadi J; Sansary J; Rosenberg M
AIDS; 2009 Jan; 23(3):403-7. PubMed ID: 19114857
[TBL] [Abstract][Full Text] [Related]
7. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection.
Chantry CJ; Byrd RS; Englund JA; Baker CJ; McKinney RE;
Pediatr Infect Dis J; 2003 Dec; 22(12):1033-9. PubMed ID: 14688560
[TBL] [Abstract][Full Text] [Related]
8. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?
Newell ML; Patel D; Goetghebuer T; Thorne C;
J Infect Dis; 2006 Apr; 193(7):954-62. PubMed ID: 16518757
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).
Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J
Clin Infect Dis; 2010 Jul; 51(2):214-24. PubMed ID: 20536367
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up outcomes of perinatally HIV-infected adolescents: infection control but school failure.
Souza E; Santos N; Valentini S; Silva G; Falbo A
J Trop Pediatr; 2010 Dec; 56(6):421-6. PubMed ID: 20167634
[TBL] [Abstract][Full Text] [Related]
11. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
[TBL] [Abstract][Full Text] [Related]
13. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
Palacios R; Senise J; Vaz M; Diaz R; Castelo A
HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
[TBL] [Abstract][Full Text] [Related]
14. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
15. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
16. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
[TBL] [Abstract][Full Text] [Related]
17. Anti-HIV-1 antibody avidity is correlated with clinical status in infected children.
Sciascia C; Palomba E; Gay V; Tovo PA
Pediatr AIDS HIV Infect; 1996 Feb; 7(1):14-9. PubMed ID: 11361468
[TBL] [Abstract][Full Text] [Related]
18. [T-cell subsets variation during clinical and immunological progression in vertically HIV-infected children].
Resino García S; Bellón Cano JM; Navarro Caspistegui J; Gurbindo Gutiérrez D; León Leal JA; Muñoz-Fernández MA
Medicina (B Aires); 2001; 61(5 Pt 1):557-65. PubMed ID: 11721322
[TBL] [Abstract][Full Text] [Related]
19. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
Chiappini E; Galli L; Tovo PA; Gabiano C; Gattinara GC; Guarino A; Badolato R; Giaquinto C; Lisi C; de Martino M;
AIDS; 2006 Jan; 20(2):207-15. PubMed ID: 16511413
[TBL] [Abstract][Full Text] [Related]
20. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
Sperling RS; Shapiro DE; Coombs RW; Todd JA; Herman SA; McSherry GD; O'Sullivan MJ; Van Dyke RB; Jimenez E; Rouzioux C; Flynn PM; Sullivan JL
N Engl J Med; 1996 Nov; 335(22):1621-9. PubMed ID: 8965861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
